Volume 40, Issue 2 , Pages 217-223, August 2010
Age-Associated Differences in Fatigue Among Patients with Cancer
Abstract
Context
There has been some suggestion that the fatigue experienced by older cancer patients is more severe than that of younger cohorts; however, there is little empirical evidence to support this claim.
Objectives
The goal of the present study was to determine the differential impact of age and cancer diagnosis on ratings of fatigue using a validated self-report instrument.
Methods
The Functional Assessment of Chronic Illness Therapy-Fatigue subscale consists of 13 items measuring fatigue experience and its impact on daily life, with scores ranging from 0 (severe fatigue) to 52 (no fatigue). Fatigue data were available from the U.S. general population (n
=
1075; 51.3% female, 45.9
±
16.5 years) and a sample of mixed-diagnosis cancer patients (n
=
738; 64.3% female, 58.7
±
13.6 years). General population participants were recruited using an Internet-based survey panel; patients with cancer were recruited from Chicago-area oncology clinics.
Results
On average, the cancer patient group reported more severe fatigue than the general population group (36.9 vs. 46.6; F[1,1797]
=
271.95, P
<
0.001). There was evidence for increased fatigue with age (F[6,719]
=
2.56, P
<
0.02) among patients with cancer, but not in the general population (P
=
0.06). Furthermore, the group
×
age interaction was not significant (P
=
0.44). Hemoglobin (Hgb) was treated as a covariate for 430 patients with available data; there was no main effect for age in this analysis.
Conclusion
Older adults, whether they had a cancer diagnosis, reported more fatigue than younger adults. These differences may be explained, in part, by Hgb level. Future research would be helpful to explore longitudinal changes in fatigue in the general population and guide fatigue management for the older cancer patient.
Key Words: Fatigue, cancer, assessment, patient-reported outcome, hemoglobin
Funding source: A subset of the data analyzed for this study was collected as part of National Institutes of Health (NIH) R01 CA60068 (Principal Investigator: David Cella, PhD). Manuscript preparation supported in part by grant UL1RR025741 from the National Center for Research Resources, NIH.
Disclosures: Dr. Butt has received grant support from and served as a consultant for Ortho Biotech and has served as a consultant for Johnson & Johnson. Dr. Cella has received grant support from Ortho Biotech. The other authors have no disclosures.
PII: S0885-3924(10)00312-X
doi:10.1016/j.jpainsymman.2009.12.016
© 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
Volume 40, Issue 2 , Pages 217-223, August 2010
